Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | PD-1/VEGFR blockade for liver cancer

David Pinato • 16 Apr 2021
Gastrointestinal Cancer Liver Cancer Antibodies Atezolizumab Bevacizumab Carboplatin Paclitaxel

David Pinato, MD, MRes, PhD, Imperial College London, London, UK, discusses the use of combined PD-1/VEGFR blockade for the treatment of hepatocellular cancer, highlighting promising results with bevacizumab and atezolizumab in combination, and comparing this approach to strategies being employed in the treatment of lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Disclosures

David Pinato, MD, MRes, PhD, has received lecture fees from ViiV Healthcare and Bayer Healthcare; has received travel expenses from BMS and Bayer Healthcare; has received consulting fees from Mina Therapeutics, EISAI, Roche and Astra Zeneca; and has received research funding (to the institution) from MSD and BMS.

More from David Pinato

3:22
COVID-19 and cancer outcomes in the UK
David Pinato • 19 Apr 2021
2:03
Antibiotics impact outcomes with pembrolizumab in NSCLC patients
David Pinato • 16 Apr 2021
1:00
PRIME-HCC: ipilimumab and nivolumab in liver cancer
David Pinato • 16 Apr 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals